The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

AdChoices
 

Nektar Therapeutics

Nasdaq: NKTR
Last

(U.S.) $13.28

Today's change+0.33 +2.55%
Updated December 9 4:00 PM EST. Delayed by at least 15 minutes.
 

Nektar Therapeutics

Nasdaq: NKTR
Last

(U.S.) $13.28

Today's change+0.33 +2.55%
Updated December 9 4:00 PM EST. Delayed by at least 15 minutes.

Nektar Therapeutics crosses above 20-day moving average

Nektar Therapeutics closed up sharply Friday, rallying (U.S.)$0.33 or 2.55% to (U.S.)$13.28 and crossing above its 20-day moving average. Over the last five days, shares have gained 7.36%, but are down 21.19% for the last year to date. Shares have underperformed the S&P 500 by 25.60% during the last year.

Key company metrics

  • Open(U.S.) $13.06
  • Previous close(U.S.) $12.95
  • High(U.S.) $13.40
  • Low(U.S.) $12.98
  • Bid / Ask(U.S.) $12.86 / (U.S.) $15.20
  • YTD % change-21.19%
  • Volume1,984,026
  • Average volume (10-day)1,334,205
  • Average volume (1-month)1,851,393
  • Average volume (3-month)1,591,576
  • 52-week range(U.S.) $10.52 to (U.S.) $19.98
  • Beta1.86
  • Trailing P/ENegative, not meaningful
  • P/E 1 year forwardNegative, not meaningful
  • Forward PEGNegative, not meaningful
  • Indicated annual dividend--
  • Dividend yield0.00%
  • Trailing EPS(U.S.) -$1.22
Updated December 9 4:00 PM EST. Delayed by at least 15 minutes.

Profit

Net Profit (TTM)
-98.87%

Although this company's net profit margin is negative, it is above the industry average and implies that Nektar Therapeutics is operating more effectively than other companies in the industry.
Company Books

S&P TSX0.11%Sector:HealthcareIndustry:Biotechnology
  • Income Statement
  • Balance Sheet
  • Cash Flow
Quarter | Annual
Q3/2016Q2/2016Q1/2016Q4/2015
Fiscal Quarter Endvalues in (U.S.) $ millions unless otherwise notedSep 30, 201609/30/2016Jun 30, 201606/30/2016Mar 31, 201603/31/2016Dec 31, 201512/31/2015
Revenue36335939
Total other revenue--------
Total revenue36335939
Gross profit29255031
Total cost of revenue7898
Total operating expense69716883
Selling / general / administrative10111013
Research & development52524947
Depreciation / amortization--------
Interest expense (income), net operating--------
Unusual expense (income)------14
Other operating expenses, total--------
Operating income-33-38-9-43
Interest income (expense), net non-operating-11-11-11-11
Gain (loss) on sale of assets--------
Other--------
Income before tax-43-48-19-54
Income after tax-43-49-19-54
Income tax, total0000
Net income-43-49-19-54
Total adjustments to net income--------
Net income before extra. items-43-49-19-54
Minority interest--------
Equity in affiliates--------
U.S. GAAP adjustment--------
Inc. avail. to common excl. extra. items-43-49-19-54
Inc. avail. to common incl. extra. items-43-49-19-54
Diluted net income-43-49-19-54
Dilution adjustment----0--
Diluted weighted average shares137136136134
Diluted EPS excluding extraordinary itemsvalue per share-0.32-0.36-0.14-0.40
Dividends per sharevalue per share0.000.000.00--
Diluted normalized EPSvalue per share-0.32-0.36-0.14-0.34